Full Text | PDF

J Cancer 2018; 9(20):3765-3775. doi:10.7150/jca.25576 This issue Cite

Review

MicroRNA-34 family in breast cancer: from research to therapeutic potential

Saber Imani ¹, Ray-Chang Wu ², Junjiang Fu ^{1 ✉}

1. Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
2. Department of Biochemistry and Molecular Medicine, the George Washington University, Washington, DC 20052, USA.

✉ Corresponding author: Tel-fax: +86-830-3160283. E-mail: fujunjiangedu.cn and fujunjiangcom.

Abstract

MicroRNA (miRNA)-34 family (miR-34s), including miR-34a/b/c, is the most well studied non-coding RNAs that regulate gene expression post-transcriptionally. The miR-34s mediates the tumor suppressor function of p53 in the pathogenesis of breast cancer by targeting different oncogenes. This review focuses on the anti-oncogenic regulation of the miR-34s, emphasizing the major signaling pathways that are involved in the modulation of miR-34s in breast cancer. Moreover, it highlights how epigenetic modification by the p53/miR-34s axis regulates the proliferation, invasiveness, chemoresistance, and sternness of breast cancer. A better understanding of the molecular mechanisms of miR-34s will open new opportunities for the development of novel therapeutic strategies and define a new approach in identifying potential biomarkers for early diagnosis of breast cancer.

Keywords: MicroRNA-34, Breast cancer, Tumor suppressor miRNA, Diagnosis, Treatment.

Citation styles

©2024 Ivyspring International Publisher. Terms of use